Friday, April 05, 2019 1:09:08 PM
The Anavex story is not how well it’s being told or heard. It’s that, for still so many, it’s simply unbelieved. “Nope, no drug can possibly ____________!” Fill in the blanks. Use phrases like, “treat Alzheimer’s,” “prevent senile dementia,” “fix Parkinson’s,” etc.
Anavex Life Sciences Corp is a tiny, unknown biotech startup. No approved drugs to sell. No full, complete, detailed Phase 3 fully-blinded multi-arm clinical trials on humans. Too good to be true. Lots of really smart MDs and PhDs have spent real billions of dollars testing drugs to fix the Central Nervous System biggies, and have failed in every case. Self-perceived smart people (of the investments type) know better. There’s not a thing in the Anavex story book that will result in a real drug, with real sales.
Those people stopped reading the Anavex story book in the second chapter, when I and a bunch of others detailed the multiple mechanisms of action of Anavex 2-73 inside malfunctioning neurons. Recently, a paper was published in a recognized, peer-reviewed journal telling just what I and the other science-types have been saying about Anavex 2-73 on this message board. The stuff works (restores or maintains a number of essential chemical pathways in neurons), just as we’ve described (facilitated proper protein folding to make functional reaction-controlling enzymes, etc.). Actually, all of that was, indeed, beyond their considered comprehension. When reading the science of Anavex, instead of light bulbs lighting up in the readers’ cerebra, only big question marks ascended into thought streams.
For those of us with well-considered long AVXL positions, what are the implications of what I’ve just described? The investment communities, retail (individuals, like myself), mutual funds, pension funds, etc. simply aren’t going to start taking AVXL positions until they are assured of a future, ascending value for AVXL shares. That, to them, has nothing to do with the arcane, inscrutable chemical science of Anavex 2-73. It has to do with the assured prospects of some government’s sales approval of the drug; whether by the FDA here, or perhaps more promptly by the Australian drug approval agency.
And all of that, like everything else, hinges on positive clinical trial outcomes. Will those be from the handful of older girls or young women in the Rett trial? Or, Parkinson’s patients in the trial in Spain? Both of those are much shorter than the big three-arm Alzheimer’s trial.
There will be big buying of Anavex stocks when any of the investment communities read about, “New Anavex drug shows great results in completed trial.” Then, few will care a whit about the biochemistry of the Anavex molecule. The only issues of contention will be the eventual sizes of the Anavex market (number of patients), and how soon the drug can be manufactured and sold. Our discussions about the details of Anavex science will be but curious, historical anecdotes.
Recent AVXL News
- Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024 • GlobeNewswire Inc. • 09/03/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 09:21:05 PM
- Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/06/2024 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 09:20:53 PM
- Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/29/2024 09:21:49 PM
- Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference • GlobeNewswire Inc. • 07/28/2024 09:00:00 PM
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM
Element79 Gold Corp Announces 2024 Clover Work Plans & Nevada Portfolio Updates • ELMGF • Sep 10, 2024 11:00 AM
Nightfood Holdings Inc. Completes Major Step on Uplist Journey by Closing Strategic All-Stock Acquisition of CarryoutSupplies.com • NGTF • Sep 10, 2024 8:15 AM
Element79 Gold Corp. Announces Sale of 100% Interest in Elder Creek, North Mill Creek, and Elephant Projects to 1472886 B.C. Ltd. • ELEM • Sep 9, 2024 9:34 AM